文献速递炎症性肠病

综述:炎症性肠病患者阿达木单抗与英夫利西单抗治疗药物监测治疗范围的确定

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-01-21

该综述系统回顾了确定抗TNF药物(英夫利西单抗和阿达木单抗)治疗范围的方法学,并比较两者在炎症性肠病中的应用。43项研究中,药物浓度测量时间、终点、临床场景及TDM原因差异巨大;英夫利西单抗维持期谷浓度下限为2.8-5.7 µg/mL(AUROC 0.68-0.77),阿达木单抗为5.9-11.8 µg/mL(AUROC 0.66-0.83),但部分研究未找到显著截断值。英夫利西单抗的暴露-反应证据强于阿达木单抗。

要点

  • 英夫利西单抗维持期谷浓度下限2.8-5.7 µg/mL,AUROC 0.68-0.77。
  • 阿达木单抗治疗范围下限5.9-11.8 µg/mL,AUROC 0.66-0.83,但部分研究无显著截断值。
  • 治疗范围受测量时间、终点、临床场景和TDM原因异质性影响,解读需谨慎。

核心结论

  • 英夫利西单抗的暴露-反应关系证据强于阿达木单抗。
  • 由于药物浓度测量场景异质性,治疗范围存在变异,解读证据时需考虑这些因素。

研究设计与样本

  • 系统综述,共纳入43项研究,总结并批判性审查相关文献。

主要发现

  • 43项研究中,英夫利西单抗和阿达木单抗的测量时间、终点(从临床缓解到黏膜愈合)、临床场景(活动期vs维持期)及TDM原因(主动vs被动)存在巨大差异。
  • 英夫利西单抗维持期谷浓度下限为2.8-5.7 µg/mL(取决于终点),AUROC一致为0.68-0.77。
  • 阿达木单抗TDM目标下限为5.9-11.8 µg/mL(AUROC 0.66-0.83),但部分研究未识别出与结局显著相关的截断值。

关键数值与推荐

  • 英夫利西单抗维持期谷浓度下限2.8-5.7 µg/mL,AUROC 0.68-0.77。
  • 阿达木单抗下限5.9-11.8 µg/mL,AUROC 0.66-0.83,但部分研究无显著截断值。

临床怎么用

  • 临床解读TDM结果时需考虑测量时间、终点、疾病阶段及TDM原因等异质性因素。

局限性

  • 研究间存在异质性,包括药物浓度测量时间、终点、临床场景和TDM原因不同。
  • 阿达木单抗的药代动力学和药效学差异及研究设计异质性导致部分研究无法确定显著截断值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical application of therapeutic drug monitoring (TDM) to optimise anti-TNF therapies in patients with IBD depends upon target ranges. AIMS: To review methodology used to determine therapeutic ranges and critically compare and contrast its application to infliximab and adalimumab. METHODS: A systematic review was performed, and relevant literature was summarised and critically examined. RESULTS: Upper limits of the therapeutic range are determined by toxicity, a plateau response and cost. Lower limits are determined by optimal concentration on the target of action in vitro and/or in vivo, or by correlation of drug levels with clinical efficacy using area-under-receiver-operator-curve (AUROC) analysis. In 43 studies, there were huge variations in time at which infliximab and adalimumab levels were measured, the end-points used (clinical remission to mucosal healing), the clinical setting (active disease vs maintenance phase) and the reason for TDM (proactive vs reactive). In the maintenance phase for infliximab, lower trough limits 2.8-5.7 µg/mL are reported depending upon end-points used, with consistent AUROC 0.68-0.77. Adalimumab TDM targets are even less consistent with a lower limit 5.9-11.8 µg/mL (AUROC 0.66-0.83) in some studies, but no cut-off can be identified that is significantly associated with outcome in others, related to inherent pharmacokinetic and pharmacodynamic differences, and heterogeneity of study design. CONCLUSIONS: Evidence for exposure-response relationship is stronger for infliximab than adalimumab. Due to heterogeneity in settings for drug level measurements, therapeutic ranges vary. These factors need to be taken into account when interpreting the evidence and extending this to therapeutic strategies for IBD patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Gibson DJ, Ward MG, Rentsch C, et al. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 31961001. doi:10.1111/apt.15643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。